Rheumatoid arthritis (RA) is a systemic inflammatory disorder, with the most common extra-
articular manifestation of RA being lung involvement. While essentially any of the lung …

Interstitial lung disease (ILD) secondary to drug-induced lung injury is an increasingly
common cause of morbidity and mortality. The number of drugs associated with the …

Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease affecting 0.5–1%
of the population worldwide. Interstitial lung disease (ILD) is a serious pulmonary …

Objectives MTX is the most commonly recommended DMARD for first-line treatment of RA,
however, it has been hypothesized to cause lung disease as an adverse effect. We …

Objective This study explores whether the prognosis of interstitial lung disease in
rheumatoid arthritis (RA-ILD) has improved over time and assesses the potential influence of …

Rationale: Development of novel nanomedicines to inhibit pro-inflammatory cytokine
expression and reactive oxygen species (ROS) generation for anti-inflammatory therapy of …

Rheumatoid arthritis (RA) is a systemic inflammatory disease, which primarily causes
symmetric polyarthritis. An extrarticolar involvement is common, and the commonly involved …

Background: Treatment of rheumatoid arthritis (RA)-related interstitial lung disease (ILD) is
challenging, and many conventional and biologic disease-modifying anti-rheumatic drugs …

Background Pulmonary fibrosis is characterized by lung parenchymal destruction and can
increase morbidity and mortality. Pulmonary fibrosis commonly occurs following …

Rheumatoid arthritis (RA) is a common type of autoimmune arthritis. Patient clinical
outcomes might be influenced by numerous respiratory diseases, but interstitial lung …